A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1
← catalyst calendarNCT06667453 · readout ≤ 224 d
Sponsored by PepGen Inc (industry) · PEPG — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
24estimated
Sites
12
Countries
Canada, New Zealand, South Korea +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-10 | actual | When the study began enrolling |
| Primary completion | Mar 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myotonic Dystrophy 1
Interventions
- Drug: PGN-EDODM1
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFSafety and tolerability as assessed by number of participants with Adverse Events (AEs)
measured Baseline through Day 112
Permalink · PEPG's whole pipeline · Catalyst calendar · Every registered study · What changed